Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018)



Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ
et al (show 28 more authors) (2019) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018). ANNALS OF ONCOLOGY, 30 (12). pp. 2013-2014.

[thumbnail of Adjuvant bevacizumab for melanoma patients at high risk of recurrence survival analysis of the AVAST-M trial.pdf] Text
Adjuvant bevacizumab for melanoma patients at high risk of recurrence survival analysis of the AVAST-M trial.pdf - Published version

Download (816kB) | Preview

Abstract

In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article.

Item Type: Article
Uncontrolled Keywords: Clinical Research, Cancer, Clinical Trials and Supportive Activities
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 22 Dec 2021 09:19
Last Modified: 07 Jun 2024 12:36
DOI: 10.1093/annonc/mdz237
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3145823